Cancers, Vol. 11, Pages 1055: Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Cancers, Vol. 11, Pages 1055: Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Cancers doi: 10.3390/cancers11081055
Authors:
Ernesto Rossi
Giovanni Schinzari
Ilaria Grazia Zizzari
Brigida Anna Maiorano
Monica Maria Pagliara
Maria Grazia Sammarco
Vincenzo Fiorentino
Gianluigi Petrone
Alessandra Cassano
Guido Rindi
Emilio Bria
Maria Antonietta Blasi
Marianna Nuti
Giampaolo Tortora
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Source: Cancers - Category: Cancer & Oncology Authors: Ernesto Rossi Giovanni Schinzari Ilaria Grazia Zizzari Brigida Anna Maiorano Monica Maria Pagliara Maria Grazia Sammarco Vincenzo Fiorentino Gianluigi Petrone Alessandra Cassano Guido Rindi Emilio Bria Maria Antonietta Blasi Marianna Nuti Giampaolo Tortor Tags: Review Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Clinical Trials | Eye Cancers | Immunotherapy | Melanoma | Skin Cancer | Uveal Melanoma